查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750781

思覺失調症藥物市場規模、佔有率、趨勢分析報告（按藥物類別、給藥途徑、分銷管道、地區、細分市場預測），2025 年至 2030 年

Schizophrenia Drugs Market Size, Share & Trends Analysis Report By Drug Class (Second- generation Antipsychotics, Third-Generation Antipsychotics), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

思覺失調症藥物市場的成長與趨勢：

根據 Grand View Research, Inc. 的一份新報告，全球思覺失調症藥物市場預計到 2030 年將達到 112 億美元，2025 年至 2030 年的複合年成長率為 5.6%。

預計思覺失調症市場將受到藥物傳輸技術的改進、長效注射劑 (LAI) 的可用性、尋求治療的患者數量的增加等因素的全面推動。推動新藥採用的關鍵特徵被認為是起效快、患者易於獲得、效率高和患者依從性高。

思覺失調症對患者、患者家屬乃至整個社會帶來了沉重的負擔。患者和醫生對精神疾病（尤其是思覺失調症）的認知不斷提高，可能會推動新藥的市場滲透。目前，第二代和第三代抗精神病藥物佔據了很大的市場佔有率。臨床試驗中的在研藥物旨在透過阻斷特定亞型的血清素和/或多巴胺受體來減輕症狀、調節升高的多巴胺水平，甚至改善記憶力。

雖然預計思覺失調症市場的成長將主要由後期研發線產品的湧現推動，例如Intra-Cellular Therapies的ITI-007和Alkermes的ALKS-3831，這些產品旨在治療陰性症狀，但思覺失調症治療領域仍存在大量未滿足的需求。然而，由於對確切疾病機制的理解不足，阻礙了突破性療法的發現，思覺失調症治療領域仍存在大量未滿足的需求。因此，需要藥物傳遞技術的創新來治療這種令人衰弱的疾病。

思覺失調症藥物市場報告重點

  • 2024 年，第二代抗精神病藥物佔據最大的市場收入佔有率，為 73.05%。與第一代抗精神病藥物相比，第二代抗精神病藥物的安全性和有效性有所提高，因此思覺失調症治療市場對第二代抗精神病藥物的需求正在增加。
  • 2024年，注射型抗精神病藥物治療領域佔據了最大的市場收入佔有率。由於注射型抗精神病藥物能夠應對與疾病相關的許多挑戰，其需求正在不斷成長。注射劑，尤其是長效注射劑 (LAI)，能夠持續釋放藥物，有助於維持治療水平，並降低因漏服而導致復發的風險，而漏服是口服藥物常見的問題。
  • 2024 年，醫院藥局部門佔據了最大的市場收入佔有率。醫院藥局能夠提供全面的護理，包括管理複雜的用藥方案和監測副作用。
  • 2024 年，北美思覺失調症藥物市場佔最大市場收入佔有率，為 38.65%。這歸因於人們對思覺失調症及相關精神障礙的認知和診斷率的提高。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章。思覺失調症藥物市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 思覺失調症藥物市場分析工具
    • 產業分析—波特五力分析
    • PESTEL分析
    • 定價分析
    • 管道分析

第4章思覺失調症藥物市場：藥物類別估計與趨勢分析

  • 全球思覺失調症藥物市場：藥物類別儀表板
  • 全球思覺失調症藥物市場：藥物類別差異分析
  • 全球思覺失調症藥物市場（按類別和收益）
  • 第二代抗精神病藥物
  • 第三代抗精神病藥物

第5章思覺失調症藥物市場：給藥途徑評估與趨勢分析

  • 全球思覺失調症藥物市場：給藥途徑儀表板
  • 全球思覺失調症藥物市場：給藥途徑變化分析
  • 全球思覺失調症藥物市場按給藥途徑和收益
  • 口服抗精神病藥
  • 注射抗精神病藥物

第6章思覺失調症藥物市場：分銷管道評估與趨勢分析

  • 全球思覺失調症藥物市場：分銷通路儀表板
  • 全球思覺失調症藥物市場：分銷管道變化分析
  • 全球思覺失調症管道和收益
  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 其他

第7章思覺失調症藥物市場：區域估計與趨勢分析、按藥物類別、按分銷管道、按給藥途徑

  • 區域儀表板
  • 2018-2030 年市場規模、預測與趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 主要客戶
    • 2024年主要企業市場佔有率分析
    • Johnson &Johnson Services, Inc.
    • Bristol-Myers Squibb Company/Otsuka Holdings Co., Ltd.
    • Sumitomo Pharma Co., Ltd.
    • Eli Lilly and Company
    • Alkermes
    • VANDA PHARMACEUTICALS
    • AstraZeneca
    • AbbVie Inc.
    • Pfizer Inc.
    • H. Lundbeck A/S
Product Code: GVR-2-68038-222-8

Schizophrenia Drugs Market Growth & Trends:

The global schizophrenia drugs market size is expected to reach USD 11.20 billion by 2030, registering to grow at a CAGR of 5.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance.

Schizophrenia imposes substantial burden on patients, their families and the overall society. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve memory.

The growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating disorder.

Schizophrenia Drugs Market Report Highlights:

  • The second-generation-antipsychotics held the largest market revenue share of 73.05% in 2024. The demand for second-generation antipsychotics in the schizophrenia drugs market is rising due to their improved safety and efficacy profiles compared to first-generation antipsychotics.
  • The injectable antipsychotics treatment segment held the largest market revenue share in 2024. The demand for injectable antipsychotics is on the rise due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications.
  • The hospital pharmacies segment held the largest market revenue share in 2024. Hospital pharmacies are well-positioned to provide comprehensive care, including managing complex medication regimens and monitoring side effects, which are critical for this condition.
  • North America schizophrenia drugs market held the largest market revenue share of 38.65% in 2024. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Class
    • 1.2.2. Treatment
    • 1.2.3. Treatment
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class and Route of Administration Outlook
    • 2.2.2. Distribution Channel Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Schizophrenia Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Schizophrenia Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
      • 3.3.4.1. Phase 1
      • 3.3.4.2. Phase 2
      • 3.3.4.3. Phase 2

Chapter 4. Schizophrenia Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Global Schizophrenia Drugs Market: Drug Class Dashboard
  • 4.2. Global Schizophrenia Drugs Market: Drug Class Movement Analysis
  • 4.3. Global Schizophrenia Drugs Market by Class, Revenue
  • 4.4. Second-Generation Antipsychotics
    • 4.4.1. Second-Generation Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1. Risperdal (Risperidone)
        • 4.4.1.1.1. Risperdal (Risperidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Invega (Paliperidone)
        • 4.4.1.2.1. Invega (Paliperidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Zyprexa (Olanzapine)
        • 4.4.1.3.1. Zyprexa (Olanzapine) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Geodon (Ziprasidone)
        • 4.4.1.4.1. Geodon (Ziprasidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Seroquel (Quetiapine)
        • 4.4.1.5.1. Seroquel (Quetiapine) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.6. Latuda (Lurasidone)
        • 4.4.1.6.1. Latuda (Lurasidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.7. Aristada (Aripiprazole Lauroxil)
        • 4.4.1.7.1. Aristada (Aripiprazole Lauroxil) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.8. Fanapt (Iloperidone)
        • 4.4.1.8.1. Fanapt (Iloperidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.9. Vraylar (Cariprazine)
        • 4.4.1.9.1. Vraylar (Cariprazine) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Third-Generation Antipsychotics
    • 4.5.1. Schizophrenia Drugs market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Schizophrenia Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global Schizophrenia Drugs Market: Route of Administration Dashboard
  • 5.2. Global Schizophrenia Drugs Market: Route of Administration Movement Analysis
  • 5.3. Global Schizophrenia Drugs Market by Route of Administration , Revenue
  • 5.4. Oral Antipsychotics
    • 5.4.1. Oral Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Injectable Antipsychotics
    • 5.5.1. Injectable Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Schizophrenia Drugs Market: Distribution Channel Dashboard
  • 6.2. Global Schizophrenia Drugs Market: Distribution Channel Movement Analysis
  • 6.3. Global Schizophrenia Drugs Market by Distribution Channel, Revenue
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Distribution Channel, and Route of Administration

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Johnson & Johnson Services, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Class benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Bristol-Myers Squibb Company/ Otsuka Holdings Co., Ltd.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Class benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Sumitomo Pharma Co., Ltd.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Class benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Eli Lilly and Company
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Class benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Alkermes
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Class benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. VANDA PHARMACEUTICALS
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Class benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. AstraZeneca
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Class benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. AbbVie Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Class benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Pfizer Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Class benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. H. Lundbeck A/S
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Class benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 3 North America Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 4 North America Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 U.S. Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 6 U.S. Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 U.S. Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 Canada Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9 Canada Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 Canada Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Mexico Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 Mexico Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Mexico Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Europe Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Europe Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 Europe Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Germany Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Germany Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Germany Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 UK Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 21 UK Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 UK Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 France Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 24 France Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 France Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Italy Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Italy Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 Italy Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Spain Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 30 Spain Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 Spain Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 China Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 36 China Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 China Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Japan Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Japan Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Japan Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 India Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 42 India Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 India Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 South Korea Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 45 South Korea Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 South Korea Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Latin America Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 48 Latin America Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 Latin America Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Brazil Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Brazil Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Brazil Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 MEA Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 54 MEA Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 MEA Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 South Africa Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 57 South Africa Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 South Africa Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 UAE Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 63 UAE Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 UAE Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Schizophrenia Drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug Class and Route of Administration segment snapshot
  • Fig. 10 Route of Administration segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Pharmaceutical market, (USD Billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Schizophrenia Drugs market: Drug Class Outlook and key takeaways
  • Fig. 17 Schizophrenia Drugs market: Drug Class movement analysis
  • Fig. 18 Second-Generation Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Risperdal (Risperidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Invega (Paliperidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Zyprexa (Olanzapine) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Geodon (Ziprasidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Seroquel (Quetiapine) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Latuda (Lurasidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Aristada (Aripiprazole Lauroxil) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Fanapt (Iloperidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Saphris (Asenapine) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Vraylar (Cariprazine) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Third-Generation Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Abilify (Aripiprazole) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Schizophrenia Drugs market: Route of Administration Outlook and key takeaways
  • Fig. 33 Schizophrenia Drugs market: Route of Administration movement analysis
  • Fig. 34 Oral Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Injectable Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Schizophrenia Drugs market: Distribution Channel Outlook and key takeaways
  • Fig. 37 Schizophrenia Drugs market: Distribution Channel movement analysis
  • Fig. 38 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Schizophrenia Drugs market revenue, by region, 2024 & 2030, (USD Million)
  • Fig. 43 Regional marketplace: Key takeaways
  • Fig. 44 North America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Target disease prevalence
  • Fig. 47 U.S. schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Target disease prevalence
  • Fig. 50 Canada schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Target disease prevalence
  • Fig. 54 Europe schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Target disease prevalence
  • Fig. 57 UK schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Target disease prevalence
  • Fig. 60 Germany schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Target disease prevalence
  • Fig. 63 France schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Target disease prevalence
  • Fig. 66 Spain schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Target disease prevalence
  • Fig. 69 Italy schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Target disease prevalence
  • Fig. 72 Denmark schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Target disease prevalence
  • Fig. 75 Sweden schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Target disease prevalence
  • Fig. 78 Norway schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Rest of Europe schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Asia Pacific schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Target disease prevalence
  • Fig. 83 Japan schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Target disease prevalence
  • Fig. 86 China schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Target disease prevalence
  • Fig. 89 India schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Target disease prevalence
  • Fig. 92 Australia schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Thailand schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 South Korea schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Rest of Asia Pacific schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Latin America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Target disease prevalence
  • Fig. 101 Brazil schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Target disease prevalence
  • Fig. 104 Argentina schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Rest of Latin America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 MEA schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 Target disease prevalence
  • Fig. 109 South Africa schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key country dynamics
  • Fig. 111 Target disease prevalence
  • Fig. 112 Saudi Arabia schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 Target disease prevalence
  • Fig. 115 UAE schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Key country dynamics
  • Fig. 117 Target disease prevalence
  • Fig. 118 Kuwait schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Rest of MEA schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)